A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 13 Feb 2013
Price :
$35 *
At a glance
- Drugs Gefitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 16 Sep 2005 New trial record.